Aptevo Therapeutics (APVO) Given Media Impact Score of 0.08

Press coverage about Aptevo Therapeutics (NASDAQ:APVO) has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aptevo Therapeutics earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.7132029274009 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

A number of research analysts recently commented on the company. ValuEngine cut Aptevo Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, November 10th. Piper Jaffray Companies reissued an “overweight” rating and issued a $6.00 price target on shares of Aptevo Therapeutics in a report on Thursday, October 5th.

Aptevo Therapeutics (NASDAQ:APVO) traded down $0.12 during midday trading on Friday, reaching $3.34. The company had a trading volume of 259,500 shares, compared to its average volume of 360,175. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.67 and a current ratio of 7.76. Aptevo Therapeutics has a one year low of $1.15 and a one year high of $4.85.

Aptevo Therapeutics (NASDAQ:APVO) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.14 EPS for the quarter, missing the Zacks’ consensus estimate of $2.25 by ($2.11). Aptevo Therapeutics had a negative return on equity of 28.03% and a net margin of 5.40%. equities analysts forecast that Aptevo Therapeutics will post 0.43 earnings per share for the current year.

In other Aptevo Therapeutics news, VP Randy Joe Maddux purchased 25,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The shares were bought at an average cost of $2.76 per share, with a total value of $69,000.00. Following the acquisition, the vice president now owns 25,000 shares in the company, valued at $69,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 15.60% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: “Aptevo Therapeutics (APVO) Given Media Impact Score of 0.08” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/01/19/aptevo-therapeutics-apvo-given-media-impact-score-of-0-08.html.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.

Insider Buying and Selling by Quarter for Aptevo Therapeutics (NASDAQ:APVO)

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit